• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂蛋白(a)水平高可预测慢性心力衰竭患者心力衰竭再发:一项队列研究。

High Level of Lipoprotein(a) as Predictor for Recurrent Heart Failure in Patients with Chronic Heart Failure: a Cohort Study.

机构信息

Huadu District People's Hospital, Southern Medical University - Cardiology, Guangzhou - China.

Huadu District People's Hospital, Southern Medical University - Intensive Care Unit., Guangzhou - China.

出版信息

Arq Bras Cardiol. 2019 Jul 18;113(2):197-204. doi: 10.5935/abc.20190120.

DOI:10.5935/abc.20190120
PMID:31340235
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6777886/
Abstract

BACKGROUND

Elevated plasma levels of Lipoprotein(a) [Lp(a)] are recognized as a significant risk factor for atherosclerotic vascular disease. However, there are limited data regarding association between Lp(a) and recurrent heart failure (HF) in patients with chronic HF caused by coronary heart disease (CHD).

OBJECTIVE

Elevated levels of Lp(a) might have a prognostic impact on recurrent HF in patients with chronic HF caused by CHD.

METHODS

A total of 309 patients with chronic HF caused by CHD were consecutively enrolled in this study. The patients were divided into 2 groups according to whether Lp(a) levels were above or below the median level for the entire cohort (20.6 mg/dL): the high Lp(a) group (n = 155) and the low Lp(a) group (n = 154). A 2-sided p < 0.05 was statistically considered significant.

RESULTS

During the median follow-up period of 186 days, 31 cases out of a total of 309 patients (10.03%) could not be reached during follow-up. A Kaplan-Meier analysis demonstrated that patients with higher Lp(a) levels had a higher incidence of recurrent HF than those with lower Lp(a) levels (log-rank < 0.0001). A multivariate Cox regression analysis revealed that Lp(a) levels were independently correlated with the incidence of recurrent HF after adjustment of potential confounders (hazard ratio: 2.720, 95 % confidence interval: 1.730-4.277, p < 0.0001).

CONCLUSIONS

In Chinese patients with chronic HF caused by CHD, elevated levels of Lp(a) are independently associated with recurrent HF.

摘要

背景

脂蛋白(a) [Lp(a)]的血浆水平升高被认为是动脉粥样硬化性血管疾病的一个重要危险因素。然而,关于冠心病(CHD)引起的慢性心力衰竭(HF)患者的 Lp(a)与复发性 HF 之间的关联,数据有限。

目的

Lp(a)水平升高可能对 CHD 引起的慢性 HF 患者的复发性 HF 有预后影响。

方法

这项研究连续纳入了 309 例 CHD 引起的慢性 HF 患者。根据整个队列的 Lp(a)水平(20.6mg/dL)中位数将患者分为 2 组:高 Lp(a)组(n=155)和低 Lp(a)组(n=154)。双侧 p<0.05 被认为具有统计学意义。

结果

在中位随访 186 天期间,总共 309 例患者中有 31 例(10.03%)在随访期间无法联系到。Kaplan-Meier 分析表明,Lp(a)水平较高的患者复发性 HF 的发生率高于 Lp(a)水平较低的患者(对数秩检验<0.0001)。多变量 Cox 回归分析显示,在校正潜在混杂因素后,Lp(a)水平与复发性 HF 的发生率独立相关(风险比:2.720,95%置信区间:1.730-4.277,p<0.0001)。

结论

在中国 CHD 引起的慢性 HF 患者中,Lp(a)水平升高与复发性 HF 独立相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a83e/6777886/5f1c7bb2c722/abc-113-02-0197-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a83e/6777886/5f1c7bb2c722/abc-113-02-0197-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a83e/6777886/5f1c7bb2c722/abc-113-02-0197-g01.jpg

相似文献

1
High Level of Lipoprotein(a) as Predictor for Recurrent Heart Failure in Patients with Chronic Heart Failure: a Cohort Study.脂蛋白(a)水平高可预测慢性心力衰竭患者心力衰竭再发:一项队列研究。
Arq Bras Cardiol. 2019 Jul 18;113(2):197-204. doi: 10.5935/abc.20190120.
2
Effect of Lipoprotein (a) Levels on Long-term Cardiovascular Outcomes in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries.脂蛋白(a)水平对非阻塞性冠状动脉心肌梗死患者长期心血管结局的影响。
Am J Cardiol. 2021 Aug 1;152:34-42. doi: 10.1016/j.amjcard.2021.05.003. Epub 2021 Jun 12.
3
The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study.脂蛋白(a)与首次心力衰竭住院的关联:社区动脉粥样硬化风险研究
Atherosclerosis. 2017 Jul;262:131-137. doi: 10.1016/j.atherosclerosis.2017.05.014. Epub 2017 May 12.
4
Lp(a) [Lipoprotein(a)]-Related Risk of Heart Failure Is Evident in Whites but Not in Other Racial/Ethnic Groups.脂蛋白(a) [脂蛋白(a)]与心力衰竭风险的相关性在白人中明显,但在其他种族/族裔群体中不明显。
Arterioscler Thromb Vasc Biol. 2018 Oct;38(10):2498-2504. doi: 10.1161/ATVBAHA.118.311220.
5
Impact of Lipoprotein (a) Levels on Long-Term Outcomes in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction.脂蛋白(a)水平对冠心病伴左心室收缩功能障碍患者长期结局的影响。
Circ J. 2019 Apr 25;83(5):1047-1053. doi: 10.1253/circj.CJ-18-0970. Epub 2019 Mar 26.
6
Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction.脂蛋白(a)水平可预测急性心肌梗死后的不良血管事件。
Heart Vessels. 2016 Dec;31(12):1923-1929. doi: 10.1007/s00380-016-0823-0. Epub 2016 Mar 2.
7
Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease.脂蛋白(a)水平与冠心病患者再发事件的关系。
Heart. 2020 Aug;106(16):1228-1235. doi: 10.1136/heartjnl-2020-316586. Epub 2020 May 7.
8
Plasma Lipoprotein(a) Concentration Is Associated With the Coronary Severity but Not With Events in Stable Coronary Artery Disease Patients: A Chinese Cohort Study.血浆脂蛋白(a)浓度与冠状动脉严重程度相关,但与稳定型冠状动脉疾病患者的事件无关:一项中国队列研究。
Heart Lung Circ. 2019 Jul;28(7):1009-1017. doi: 10.1016/j.hlc.2018.05.190. Epub 2018 Jun 8.
9
Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke.首次缺血性中风后脂蛋白(a)水平与复发性血管事件
Stroke. 2017 Jan;48(1):36-42. doi: 10.1161/STROKEAHA.116.014436. Epub 2016 Nov 17.
10
Impact of lipoprotein(a) and fibrinogen on prognosis in patients with coronary artery disease: A retrospective cohort study.载脂蛋白(a)和纤维蛋白原对冠心病患者预后的影响:一项回顾性队列研究。
Technol Health Care. 2024;32(5):3317-3328. doi: 10.3233/THC-240005.

引用本文的文献

1
Lp(a) in daily clinical routine: risk-factor for both cardiovascular events and heart-failure? A retrospective analysis of the Luebeck Lp(a) heart-failure (HF) registry in patients after myocardial infarction.日常临床实践中的脂蛋白(a):心血管事件和心力衰竭的危险因素?对心肌梗死后患者的吕贝克脂蛋白(a)心力衰竭(HF)登记研究的回顾性分析
Atheroscler Plus. 2025 Jul 12;61:29-34. doi: 10.1016/j.athplu.2025.07.002. eCollection 2025 Sep.
2
Lipoprotein(a) Levels and Adverse Outcomes in Heart Failure.心力衰竭患者的脂蛋白(a)水平与不良结局
J Card Fail. 2025 Apr 4. doi: 10.1016/j.cardfail.2025.03.016.
3
Lipoprotein(a) and other risk factors in dyslipidemic patients with and without heart failure.

本文引用的文献

1
Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention.脂蛋白(a)与冠状动脉造影或经皮冠状动脉介入治疗后的长期死亡率的关联。
Clin Cardiol. 2017 Sep;40(9):674-678. doi: 10.1002/clc.22712. Epub 2017 Apr 26.
2
Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.脂蛋白(a)上的氧化磷脂引发人体动脉壁炎症和炎性单核细胞反应。
Circulation. 2016 Aug 23;134(8):611-24. doi: 10.1161/CIRCULATIONAHA.116.020838. Epub 2016 Aug 5.
3
The Future of Heart Failure Diagnosis, Therapy, and Management.
合并或未合并心力衰竭的血脂异常患者的脂蛋白(a)及其他危险因素
Arch Med Sci. 2024 Oct 16;20(5):1705-1709. doi: 10.5114/aoms/194684. eCollection 2024.
4
The functions of apolipoproteins and lipoproteins in health and disease.载脂蛋白和脂蛋白在健康和疾病中的功能。
Mol Biomed. 2024 Oct 28;5(1):53. doi: 10.1186/s43556-024-00218-7.
5
Lipoprotein(a) and heart failure: a systematic review.脂蛋白(a)与心力衰竭:一项系统评价
Heart Fail Rev. 2023 Nov;28(6):1307-1314. doi: 10.1007/s10741-023-10333-2. Epub 2023 Jul 19.
6
Lipoprotein(a), family history of cardiovascular disease, and incidence of heart failure.脂蛋白(a)、心血管疾病家族史与心力衰竭发病率
J Lipid Res. 2023 Jul;64(7):100398. doi: 10.1016/j.jlr.2023.100398. Epub 2023 Jun 3.
7
Association of lipoprotein (a) and 1 year prognosis in patients with heart failure with reduced ejection fraction.载脂蛋白(a)与射血分数降低的心力衰竭患者 1 年预后的相关性。
ESC Heart Fail. 2022 Aug;9(4):2399-2406. doi: 10.1002/ehf2.13933. Epub 2022 Apr 13.
8
A male-specific association between AGTR1 hypermethylation and coronary heart disease.AGTR1 过度甲基化与冠心病的男性特异性关联。
Bosn J Basic Med Sci. 2020 Feb 5;20(1):31-36. doi: 10.17305/bjbms.2019.4321.
9
Biomarkers in Heart Failure.心力衰竭中的生物标志物
Arq Bras Cardiol. 2019 Sep 2;113(2):205-206. doi: 10.5935/abc.20190167.
心力衰竭的诊断、治疗与管理的未来
Circulation. 2016 Jun 21;133(25):2671-86. doi: 10.1161/CIRCULATIONAHA.116.023518.
4
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.2016欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南:欧洲心脏病学会(ESC)急性和慢性心力衰竭诊断与治疗特别工作组。由ESC心力衰竭协会(HFA)特别贡献制定。
Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592. Epub 2016 May 20.
5
Intensive Management to Reduce Hospitalizations in Patients With Heart Failure.强化管理以减少心力衰竭患者的住院次数
Circulation. 2016 Apr 26;133(17):1704-7. doi: 10.1161/CIRCULATIONAHA.115.017594.
6
Structure, function, and genetics of lipoprotein (a).脂蛋白(a)的结构、功能及遗传学
J Lipid Res. 2016 Aug;57(8):1339-59. doi: 10.1194/jlr.R067314. Epub 2016 Apr 13.
7
Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction.脂蛋白(a)水平可预测急性心肌梗死后的不良血管事件。
Heart Vessels. 2016 Dec;31(12):1923-1929. doi: 10.1007/s00380-016-0823-0. Epub 2016 Mar 2.
8
Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population.脂蛋白(a)水平升高、LPA 风险基因型与普通人群心力衰竭风险增加。
JACC Heart Fail. 2016 Jan;4(1):78-87. doi: 10.1016/j.jchf.2015.08.006. Epub 2015 Dec 2.
9
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis.氧化磷脂、脂蛋白(a)与钙化性主动脉瓣狭窄的进展。
J Am Coll Cardiol. 2015 Sep 15;66(11):1236-1246. doi: 10.1016/j.jacc.2015.07.020.
10
Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery.制剂设计对烟酰胺治疗学的影响:作用机制、代谢和药物传递。
Int J Pharm. 2015 Jul 25;490(1-2):55-64. doi: 10.1016/j.ijpharm.2015.05.024. Epub 2015 May 15.